Want to see JP:4594 full AI Analyst Report?
Top Page
BrightPath Biotherapeutics Co.Ltd.
(4594)
Select Model
Select Model
Rating:50Neutral
Price Target:
¥58.00
▲(20.83% Upside)
Action:Reiterated
Date:09/09/26
The score is held back primarily by weak financial performance—sharp revenue volatility, continued large operating losses, and sustained free cash flow burn—despite low leverage. Technicals are a meaningful offset with a clear multi-timeframe uptrend and positive momentum indicators. Valuation remains constrained by loss-making status (negative P/E) and no dividend yield data.
Positive Factors
Very Low Leverage
Very low leverage reduces refinancing pressure and preserves financial flexibility while the company funds biotechnology research. The sizable asset and equity base also provides some buffer against operating volatility, allowing management more room to pursue development activities without heavy debt-service obligations.
Negative Factors
Severe Revenue Volatility
The extreme year-to-year revenue swing indicates weak commercial consistency and dependence on uneven milestone or other income. Such volatility makes it difficult to forecast operating performance, plan investment confidently, or demonstrate that the business can translate research activity into repeatable revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
Very Low Leverage
Very low leverage reduces refinancing pressure and preserves financial flexibility while the company funds biotechnology research. The sizable asset and equity base also provides some buffer against operating volatility, allowing management more room to pursue development activities without heavy debt-service obligations.
Read all positive factors
BrightPath Biotherapeutics Co.Ltd. (4594) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥8.06B
Dividend YieldN/A
Average Volume (3M)964.27K
Price to Earnings (P/E)―
Beta (1Y)0.86
Revenue Growth-94.55%
EPS Growth-6.51%
CountryJP
Employees42
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.97
Shares Outstanding138,891,300
10 Day Avg. Volume656,740
30 Day Avg. Volume964,266
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.25
Price to Sales (P/S)91636.06
P/FCF Ratio-5.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BrightPath Biotherapeutics Co.Ltd. Business Overview & Revenue Model
Company Description
BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies f...
BrightPath Biotherapeutics Co.Ltd. Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 84.00K | 1.13M | 72.00K | 5.28M | 15.41M |
| Gross Profit | 55.00K | 1.10M | -341.00K | -13.33M | -23.03M |
| EBITDA | -1.30B | -1.15B | -1.17B | -1.47B | -1.45B |
| Net Income | -1.30B | -1.15B | -1.17B | -1.49B | -1.48B |
Balance Sheet | |||||
| Total Assets | 2.60B | 1.12B | 1.23B | 1.70B | 2.77B |
| Cash, Cash Equivalents and Short-Term Investments | 2.16B | 810.47M | 1.06B | 1.53B | 2.31B |
| Total Debt | 0.00 | 25.00M | 112.50M | 0.00 | 87.50M |
| Total Liabilities | 236.41M | 195.62M | 251.27M | 133.91M | 239.73M |
| Stockholders Equity | 2.37B | 924.99M | 978.99M | 1.57B | 2.53B |
Cash Flow | |||||
| Free Cash Flow | -1.37B | -1.25B | -1.16B | -1.21B | -1.53B |
| Operating Cash Flow | -1.37B | -1.25B | -1.16B | -1.20B | -1.51B |
| Investing Cash Flow | -1.93M | -1.37M | -7.65M | -1.76M | -17.57M |
| Financing Cash Flow | 2.71B | 1.00B | 690.96M | 432.10M | 569.23M |
BrightPath Biotherapeutics Co.Ltd. Technical Analysis
Positive
48.00
Price Trends
50.18
Positive
51.48
Positive
56.62
Positive
Market Momentum
1.04
Negative
67.87
Neutral
45.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4594, the sentiment is Positive. The current price of 48 is below the 20-day moving average (MA) of 52.90, below the 50-day MA of 50.18, and below the 200-day MA of 56.62, indicating a bullish trend. The MACD of 1.04 indicates Negative momentum. The RSI at 67.87 is Neutral, neither overbought nor oversold. The STOCH value of 45.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4594.
BrightPath Biotherapeutics Co.Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ¥7.75B | 51.61 | ― | 1.51% | 4.85% | -40.57% | |
58 Neutral | ¥6.63B | 66.20 | ― | 1.52% | -9.94% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ¥20.68B | -10.64 | ― | ― | ― | 4.68% | |
50 Neutral | ¥8.06B | -4.61 | ― | ― | -94.55% | -6.51% | |
47 Neutral | ¥38.07B | 56.05 | ― | ― | -47.32% | ― | |
44 Neutral | ¥8.96B | -7.73 | ― | ― | -56.16% | 3.12% |
* General Sector Average
JP:4594
BrightPath Biotherapeutics Co.Ltd.
59.00
-15.00
-20.27%
JP:4593
Healios KK
278.00
-258.00
-48.13%
JP:4599
StemRIM Inc.
319.00
1.00
0.31%
JP:4880
CellSource Co., Ltd.
329.00
-276.92
-45.70%
JP:7096
StemCell Institute
752.00
-182.00
-19.49%
JP:7776
CellSeed Inc.
224.00
-244.00
-52.14%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.